8-K: Argenx to Acquire Forte Biosciences for $2.2 Billion

Global immunology company argenx will acquire Forte Biosciences for $77 per share in cash, adding Forte's lead drug candidate FB102 to its pipeline.

Summary

• Forte Biosciences, Inc. has entered into a definitive agreement to be acquired by argenx BV for $77 per share in cash, valuing the company at approximately $2.2 billion.
• The acquisition will be completed through a two-step process: a tender offer for all outstanding shares of Forte Biosciences, followed by a merger.
• Forte's lead drug candidate, FB102, a first-in-class anti-CD122 antibody, has shown clinical proof-of-concept in vitiligo and celiac disease.
• The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions, including regulatory approvals and the tender of at least a majority of Forte's shares.
• The acquisition is not subject to a financing condition and will be funded by argenx's existing cash reserves.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, with a strong premium paid for a promising asset and a clear strategic fit for the acquiring company.

Positives

• Acquisition price of $77 per share represents an approximately 86% premium to Forte Biosciences' volume-weighted average price since reporting positive Phase 1b data in vitiligo on July 9, 2026.
• FB102 has demonstrated clinical proof-of-concept in vitiligo and celiac disease, indicating potential for multiple autoimmune disease indications.
• The acquisition strengthens argenx's immunology portfolio with a differentiated approach targeting pathogenic T-cell and NK-cell activity.
• The transaction is fully funded by argenx's cash on hand, eliminating financing risk.
• The boards of directors of both companies have unanimously approved the transaction.

Negatives

• The transaction is subject to customary closing conditions, including regulatory approvals and the tender of a majority of Forte's shares, which could delay or prevent completion.
• Forte Biosciences will be required to pay a termination fee of $65 million under specified circumstances, such as terminating the agreement to enter into a superior proposal.
• The merger agreement contains customary no-shop restrictions, limiting Forte's ability to solicit alternative acquisition proposals.

Risks

• Uncertainties regarding the timing of the tender offer and merger completion.
• The risk that the tender offer or merger may not be completed in a timely manner or at all.
• The possibility that competing offers or acquisition proposals for Forte Biosciences may emerge.
• Failure to satisfy or waive any of the various conditions to the consummation of the tender offer or merger, including obtaining required regulatory approvals.
• The occurrence of any event, change, or other circumstance that could give rise to the termination of the merger agreement.
• The effect of the announcement or pendency of the transaction on Forte Biosciences' business, including its ability to retain key personnel and maintain relationships with suppliers.
• Potential for stockholder litigation related to the transaction, which could result in significant costs.

Future Outlook

The acquisition is expected to close in Q3 2026. Post-closing, argenx plans to advance FB102 through further clinical development for vitiligo, celiac disease, alopecia areata, and other autoimmune diseases, leveraging its development expertise and global reach.

Management Comments

• "Our Vision 2030 strategy is well-defined and on track, and our discovery, development and commercialization engines are delivering real value for patients," said Karen Massey, Chief Executive Officer of argenx.
• "The acquisition of Forte Biosciences builds on the strength of that foundation and advances our ambition to be the leading immunology innovator of the future."
• "The addition of FB102 to our portfolio aligns perfectly with the argenx playbook: compelling biology, strong clinical validation and broad potential to address patient need."
• "We are incredibly proud of what we have achieved in advancing FB102 through clinical development and firmly believe that argenx is the ideal strategic partner to unlock the full potential of this novel anti-CD122 antibody across a broad range of autoimmune diseases," said Paul A. Wagner, Ph.D., Chief Executive Officer and Chairperson of the Board of Forte Biosciences.
• "By combining FB102s promising clinical profile with argenxs proven development expertise, global reach and commercial capabilities, we have a unique opportunity to accelerate its development and maximize its impact for patients living with vitiligo, celiac disease, alopecia areata and other autoimmune conditions."

Industry Context

StockSavvy.ai notes that this acquisition aligns with the trend of larger biopharmaceutical companies acquiring innovative smaller firms to bolster their pipelines, particularly in the immunology space. Argenx's prior strategic investment in Forte Biosciences suggests a well-researched and calculated move to secure a promising asset like FB102, which targets CD122, a key pathway in autoimmune diseases.

Comparison to Industry Standards

• The acquisition price of $2.2 billion for a clinical-stage company with a lead asset in Phase 1b studies is significant, reflecting the high value placed on novel immunology assets with demonstrated clinical proof-of-concept.
• The premium of approximately 86% over the recent VWAP is substantial and indicative of the perceived value of FB102 and its potential market, especially given the unmet need in vitiligo and celiac disease.
• Argenx's strategy of acquiring companies with differentiated approaches to targeting immune cells (like T-cells and NK-cells via CD122) is consistent with industry efforts to develop more precise and effective treatments for autoimmune disorders.

Stakeholder Impact

• Shareholders of Forte Biosciences will receive $77 per share in cash, providing a significant return on their investment.
• Employees of Forte Biosciences may face uncertainty regarding their roles post-acquisition, though argenx's stated goal is to advance the pipeline.
• Patients with vitiligo, celiac disease, and other autoimmune conditions may benefit from accelerated development and potential future availability of FB102.
• Suppliers and business partners of Forte Biosciences may see changes in contractual relationships and operational integration with argenx.

Next Steps

• Commencement of a tender offer by argenx's subsidiary within 10 business days of the Merger Agreement execution.
• Filing of a Tender Offer Statement on Schedule TO by argenx and Purchaser with the SEC.
• Filing of a Solicitation/Recommendation Statement on Schedule 14D-9 by Forte Biosciences with the SEC.
• Completion of the tender offer and subsequent merger, expected in Q3 2026.
• Advancement of FB102 through further clinical development by argenx.

Key Dates

Recommendation

For existing Forte Biosciences shareholders, the $77 cash offer provides a clear and immediate exit at a significant premium, making it a favorable outcome. For argenx investors, the acquisition adds a promising asset to the pipeline, but the integration and future success of FB102 will be key drivers of long-term value, warranting a 'hold' until further clinical and commercial progress is demonstrated.

Keywords

acquisition, merger, biopharmaceutical, immunology, anti-CD122 antibody, FB102, vitiligo, celiac disease